Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 48(6); 2024 > Article
Editorial
The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
Arim Choi, Kyung-Soo Kimorcidcorresp_icon
Diabetes & Metabolism Journal 2024;48(6):1056-1057.
DOI: https://doi.org/10.4093/dmj.2024.0515
Published online: November 21, 2024
  • 283 Views
  • 48 Download

Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea

corresp_icon Corresponding author: Kyung-Soo Kim orcid Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea E-mail: kks982@hanmail.net

Copyright © 2024 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
The pathogenesis of type 2 diabetes mellitus (T2DM) has been studied for a long time. It is well established that T2DM is characterized by insulin resistance and a progressive decline in pancreatic β-cell function [1]. A prospective cohort study of 4,106 Korean people with normal glucose tolerance followed for 10 years showed that decreased β-cell function, which might be determined partly by genetic factors, and impaired β-cell compensation for progressive decline in insulin sensitivity are crucial factors in the deterioration of glucose tolerance [2]. Furthermore, interaction of a subject’s genetic makeup and their environment, the increasing prevalence of obesity, and insulin resistance and consequent increased islet amyloid polypeptide and specific types of antidiabetic agents are known to affect β-cell functions [3]. However, it is important that each individual’s β-cell function is not fixed but can continuously change.
Kim et al. [4] examined the progressive decline in β-cell function in a cohort of patients with T2DM and compared the relative importance of factors affecting insulin secretion and pancreatic β-cell function. In this study, β-cell function declined steadily over time; however, large differences in β-cell function between individuals have been reported. The β-cell function is flexible depending on the glycemic status at the time of measurement; the amount of accumulated glycosylated hemoglobin (HbA1c), variability in HbA1c levels, and type of treatment were not significantly associated with β-cell function. This study suggested that recent glycemia is a major determinant of β-cell function with a greater impact than other clinical factors, including duration of diabetes or types of antidiabetic agents in patients with T2DM.
The β-cell function and β-cell mass are associated with β-cell dysfunction and seem to be correlated with each other [5]. However, since the endogenous β-cell regenerative capacity of humans may be limited [6], preserving β-cell function is important. The β-cell function started to decline with higher plasma glucose levels, even within the range of normal plasma glucose levels, which suggested that β-cell function is already impaired prior to the development of impaired glucose tolerance (IGT) [7]. DeFronzo et al. [7] have shown that β-cell function is decreased by 80% in patients with IGT and is even lower in patients with T2DM. In the UK Prospective Diabetes Study and A Diabetes Outcome Progression Trial, treatment failure was associated with a progressive decline in β-cell function [8,9]. Thus, poor β-cell function is associated with poor glycemic control and treatment failure, indicating the important role of β-cell function in the treatment of T2DM.
Many attempts have been made to maintain β-cell function. Lifestyle modification appears to have some preservative properties on β-cell function [10]. Early intensive insulin treatment in patients with newly recognized T2DM may be effective in retarding the progressive dysfunction of β-cells [11]. Several antidiabetic agents including glucagon-like peptide-1 agonists, dipeptidyl-peptidase-4 inhibitors, and thiazolidinediones result in maintenance and often improvement of β-cell function [12]. However, no uniformly effective therapy for β-cell preservation has been found. It is especially important that the β-cell function in an individual is not fixed but constantly changes depending on the recent glycemic status. As shown in the results of Kim et al. [4], regardless of duration of diabetes or type of antidiabetic agents, recent glycemic status was most highly related to β-cell function, indicating the importance of as close as possible euglycemic control to improve β-cell function.
As patients with T2DM are increasing worldwide and the average life expectancy is also increasing, it is important to preserve beta cell function for those with T2DM to live a long and healthy life. It will be also important in reducing the pandemic burden of T2DM as a society. Appropriate glycemic control in patients with T2DM not only prevents various comorbidities and complications, but also helps preserve beta cell function, so we should make efforts to provide good glycemic control to all patients.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

  • 1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.ArticlePubMedPDF
  • 2. Ohn JH, Kwak SH, Cho YM, Lim S, Jang HC, Park KS, et al. 10-Year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabetes Endocrinol 2016;4:27-34.ArticlePubMed
  • 3. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, et al. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A 2009;106:13992-7.PubMedPMC
  • 4. Kim JY, Lee J, Kim SG, Kim NH. Recent glycemia is a major determinant of β-cell function in type 2 diabetes mellitus. Diabetes Metab J 2024;48:1135-46.ArticlePubMedPDF
  • 5. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.PubMedPMC
  • 6. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β-Cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111-7.PubMed
  • 7. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36 Suppl 2:S127-38.ArticlePubMedPMCPDF
  • 8. U.K. Prospective Diabetes Study Group. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.ArticlePubMed
  • 9. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552-60.ArticlePubMedPMCPDF
  • 10. Slentz CA, Tanner CJ, Bateman LA, Durheim MT, Huffman KM, Houmard JA, et al. Effects of exercise training intensity on pancreatic beta-cell function. Diabetes Care 2009;32:1807-11.PubMedPMC
  • 11. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-602.PubMed
  • 12. Nyalakonda K, Sharma T, Ismail-Beigi F. Preservation of betacell function in type 2 diabetes. Endocr Pract 2010;16:1038-55.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
        Diabetes Metab J. 2024;48(6):1056-1057.   Published online November 21, 2024
        Close
      • XML DownloadXML Download
      Related articles
      The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
      The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
      Choi A, Kim KS. The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus. Diabetes Metab J. 2024;48(6):1056-1057.
      DOI: https://doi.org/10.4093/dmj.2024.0515.

      Diabetes Metab J : Diabetes & Metabolism Journal
      Close layer
      TOP